Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oralgen GrassPollen in allergic rhinoconjunctivitis
NCT00824447Phase 3Completed
- Sponsor
- Artu Biologicals
- Start
- Aug 2007
- Primary completion
- Aug 2008
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines
- Countries
- 7
01
Overview
A Phase 3 trial of Oralgen Grass Pollen in allergic rhinoconjunctivitis (ARC), sponsored by Artu Biologicals. Started Aug 2007; status: completed.
02
Drugs
Oralgen Grass Pollen
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00824447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00824447.